Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor (Endometrial cohort enrolling 2nd and 3rd line patients.)
NCT Number:
NCT04008797
Phase:
I
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Lip, Oral Cavity and Pharynx, Esophagus, Stomach, Small Intestine, Colon, Rectum, Anus, Liver, Pancreas, Other Digestive Organ, Larynx, Lung, Soft Tissue, Other Skin, Ovary, Other Female Genital, Prostate, Kidney, Other Urinary, Thyroid, Bladder, Breast, Melanoma, Skin
Study Objectives:
To assess safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of
E7386 in combination with other anticancer drug(s). To assess pharmacokinetic (PK) profile of study drug(s)
To assess efficacy (objective response rate [ORR], best overall response [BOR], disease control
rate [DCR], clinical benefit rate [CBR], progression-free survival [PFS], overall survival [OS],
and duration of response [DOR]) of E7386 in combination with other anticancer drug(s)
(Revised per Amendment 06)
Study Documents
(MUSC NetID required for document access)